A
66.88
-1.23 (-1.81%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bearish |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Bearish | |
| Stock | ANI Pharmaceuticals, Inc. | Bearish | - |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| 52 Weeks Range |
36.99 - 70.81
|
|
| Price Target Range | ||
| High | 83.00 (HC Wainwright & Co., 24.10%) | Buy |
| Median | 80.00 (19.62%) | |
| Low | 77.00 (Guggenheim, 15.13%) | Buy |
| Average | 80.00 (19.62%) | |
| Total | 3 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 23 Apr 2024 | 77.00 (15.13%) | Buy | 66.14 |
| 05 Mar 2024 | 77.00 (15.13%) | Buy | 65.34 | |
| HC Wainwright & Co. | 04 Mar 2024 | 83.00 (24.10%) | Buy | 66.42 |
| Truist Securities | 01 Mar 2024 | 80.00 (19.62%) | Buy | 67.17 |
| 16 Feb 2024 | 72.00 (7.66%) | Buy | 59.72 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SHANMUGAM MUTHUSAMY | - | 65.03 | -27,232 | -1,773,771 |
| Aggregate Net Quantity | -27,232 | |||
| Aggregate Net Value ($) | -1,773,771 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHANMUGAM MUTHUSAMY | Officer | 19 Apr 2024 | Automatic sell (-) | 16,809 | 65.48 | 1,100,653 |
| SHANMUGAM MUTHUSAMY | Officer | 18 Apr 2024 | Automatic sell (-) | 10,423 | 64.58 | 673,117 |
| Date | Type | Details |
|---|---|---|
| 18 Apr 2024 | Announcement | ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET |
| 09 Apr 2024 | Announcement | ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension |
| 04 Apr 2024 | Announcement | ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis |
| 03 Apr 2024 | Announcement | ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium |
| 27 Mar 2024 | Announcement | ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP |
| 29 Feb 2024 | Announcement | ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance |
| 20 Feb 2024 | Announcement | ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference |
| 07 Feb 2024 | Announcement | ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |